Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXN6AP
|
||||
| Drug Name |
D-Arg-[Hyp3, D-NMF7, L-NMF8] Bradykinin
|
||||
| Synonyms |
CHEMBL2371658
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C56H79N15O12
|
||||
| Canonical SMILES |
CN([C@H](Cc1ccccc1)C(=O)N(C)[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)C(=O)[C@H](CO)NC(=O)[C@H](Cc3ccccc3)NC(=O)CNC(=O)[C@@H]4CC(O)CN4C(=O)[C@@H]5CCCN5C(=O)[C@H](N)CCCN=C(N)N
|
||||
| InChI |
InChI=1S/C56H79N15O12/c1-68(43(28-35-17-8-4-9-18-35)49(77)66-39(54(82)83)22-13-25-63-56(60)61)52(80)45(29-36-19-10-5-11-20-36)69(2)51(79)41(33-72)67-47(75)40(27-34-15-6-3-7-16-34)65-46(74)31-64-48(76)44-30-37(73)32-71(44)53(81)42-23-14-26-70(42)50(78)38(57)21-12-24-62-55(58)59/h3-11,15-20,37-45,72-73H,12-14,21-33,57H2,1-2H3,(H,64,76)(H,65,74)(H,66,77)(H,67,75)(H,82,83)(H4,58,59,62)(H4,60,61,63)/t37?,38-,39+,40+,41+,42+,43+,44+,45-/m1/s1
|
||||
| InChIKey |
UQNOVFWEEACSGU-ZVCMNYORSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | B1 bradykinin receptor | Target Info | [1587926] | ||
| B2 bradykinin receptor | Target Info | [1587926] | |||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Complement and coagulation cascades | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| Regulation of actin cytoskeleton | |||||
| Pathways in cancerhsa04020:Calcium signaling pathway | |||||
| cGMP-PKG signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Endocrine and other factor-regulated calcium reabsorption | |||||
| Chagas disease (American trypanosomiasis) | |||||
| Pathways in cancer | |||||
| Pathway Interaction Database | Direct p53 effectors | ||||
| Validated transcriptional targets of deltaNp63 isoforms | |||||
| WikiPathways | Complement and Coagulation Cascades | ||||
| ACE Inhibitor Pathway | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Vitamin D Receptor Pathway | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP554:ACE Inhibitor Pathway | |||||
| Nifedipine Activity | |||||
| GPCR downstream signaling | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.